IBB

Moderna has surged over 500% this year, while its closest mRNA rival remains flat. A late‑October data presentation at ESMO could either cement the rally or erase it overnight.

The Nasdaq 100 hit an intraday record driven by AI enthusiasm. Financials slid nearly 2% and crude fell for a fifth straight session.

Moderna (NASDAQ:MRNA) shares are surging Monday morning after the company announced that its Phase 3 adjuvant melanoma study for intismeran autogene, an investigational messenger RNA individualized neoantigen therapy, was selected for a Presidential Symposium slot at the European Society for Medical Oncology congress in Madrid.

HQH (abrdn Healthcare Investors) could rebound as healthcare mean reverts. The fund offers over 10% yield.

Oncology spending may reach $441B by 2029 as growth slows from generics. Five underappreciated cancer stocks are highlighted.

Anthropic is quietly setting up a biology lab while ramping its AI drug program.

Moderna climbed 6% as its cancer vaccine trade extended a 137% month. BioNTech and Novavax also edged higher.

Wall Street snapped a two-day losing streak Thursday as oil retreated from its geopolitical spike and the 10-year Treasury yield slipped back below 5%. Chipmakers led the rebound, with Intel, AMD and Micron all posting outsized gains, while gold climbed 2.5% to $4,369 an ounce.